CI Investments Inc. decreased its stake in Horizon Therapeutics Public Limited (NASDAQ:HZNP) by 23.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,271 shares of the biopharmaceutical company’s stock after selling 1,342 shares during the period. CI Investments Inc.’s holdings in Horizon Therapeutics Public were worth $332,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently modified their holdings of the company. CWM LLC increased its position in Horizon Therapeutics Public by 224.4% in the 3rd quarter. CWM LLC now owns 558 shares of the biopharmaceutical company’s stock valued at $43,000 after acquiring an additional 386 shares during the period. Steward Partners Investment Advisory LLC grew its position in Horizon Therapeutics Public by 841.2% during the third quarter. Steward Partners Investment Advisory LLC now owns 800 shares of the biopharmaceutical company’s stock worth $62,000 after buying an additional 715 shares in the last quarter. Signaturefd LLC grew its position in Horizon Therapeutics Public by 62.3% during the third quarter. Signaturefd LLC now owns 896 shares of the biopharmaceutical company’s stock worth $70,000 after buying an additional 344 shares in the last quarter. Lindbrook Capital LLC grew its position in Horizon Therapeutics Public by 469.8% during the third quarter. Lindbrook Capital LLC now owns 980 shares of the biopharmaceutical company’s stock worth $76,000 after buying an additional 808 shares in the last quarter. Finally, Captrust Financial Advisors acquired a new stake in Horizon Therapeutics Public during the second quarter worth about $59,000. 89.17% of the stock is owned by institutional investors.
In other news, EVP Irina Konstantinovsky sold 8,919 shares of the business’s stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $78.88, for a total value of $703,530.72. Following the completion of the transaction, the executive vice president now owns 36,022 shares of the company’s stock, valued at approximately $2,841,415.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Paul W. Hoelscher sold 29,576 shares of the business’s stock in a transaction on Monday, August 24th. The shares were sold at an average price of $75.76, for a total transaction of $2,240,677.76. The disclosure for this sale can be found here. Insiders have sold a total of 102,063 shares of company stock valued at $7,912,687 in the last quarter. Corporate insiders own 4.30% of the company’s stock.
Shares of Horizon Therapeutics Public stock opened at $70.15 on Friday. The firm has a fifty day moving average of $77.13 and a two-hundred day moving average of $64.21. The stock has a market capitalization of $15.48 billion, a price-to-earnings ratio of 19.17, a PEG ratio of 0.95 and a beta of 1.32. Horizon Therapeutics Public Limited has a 52 week low of $23.81 and a 52 week high of $86.67. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.45 and a current ratio of 3.49.
Horizon Therapeutics Public (NASDAQ:HZNP) last issued its earnings results on Saturday, November 7th. The biopharmaceutical company reported $1.74 EPS for the quarter, beating the consensus estimate of $0.97 by $0.77. The company had revenue of $636.40 million during the quarter, compared to analysts’ expectations of $531.11 million. Horizon Therapeutics Public had a net margin of 43.55% and a return on equity of 25.66%. The business’s revenue for the quarter was up 89.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.64 EPS. As a group, research analysts forecast that Horizon Therapeutics Public Limited will post 3.19 EPS for the current fiscal year.
Horizon Therapeutics Public Company Profile
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.
Further Reading: Calculating net profit and net profit margin ratio
Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Therapeutics Public Limited (NASDAQ:HZNP).
Receive News & Ratings for Horizon Therapeutics Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics Public and related companies with MarketBeat.com's FREE daily email newsletter.